Introduction
Calcitonin gene-related peptide (CGRP) is a 37 amino acid peptide which is produced by modification of the calcitonin gene product (Amara et al., 1982; Rosenfeld et al., 1983) . Human CGRP (hCGRP) differs by 4 amino acids from the rat CGRP .
In man it circulates in the blood at levels five times that of calcitonin (Girgis et al., 1985) , and in rodents CGRP is widely distributed in the central nervous and cardiovascular systems (Skofitsch & Jacobowitz, 1985; Mulderry et al., 1985) . CGRP is particularly abundant in perivascular nerves where it co-localizes with substance P (Lundberg et al., 1985) . In some nerves it co-exists with acetylcholine (Takami et al., 1985) . This suggests that CGRP may have a role in the control of vascular smooth muscle tone.
CGRP is a potent vasodilator in vitro, and has positive inotropic and chronotropic effects on the heart Brain et al., 1985) . Systemic administration in both rodents and man causes vasodilatation with associated tachycardia (Fischer et al., 1983; Struthers et al., 1985) . Marked dilatation of skin arterioles of rabbits and man is also seen following intradermal injection (Brain et al., 1985) . Further, hCGRP is a potent dilator of human and porcine coronary vessels (McEwan et al., 1985; Greenwald et al., 1986) .
'Author for correspondence. It remains controversial whether the vasodilatation by CGRP in vitro is dependent on the presence of an intact endothelium. Endothelium-dependent relaxation has been found in a variety of human blood vessels and in rat aorta (Brain et al., 1985; Hughes et al., 1985) but relaxation is independent ofendothelium in some rat, rabbit and cat vessels (Hanko et al., 1985; Edvinsson et al., 1985a, b (Jaffe et al., 1973 Preparation ofendothelial cellsfor perfusion studies
The release of prostacyclin from endothelial cells was measured by the perfusion of these cells attached to microcarrier beads as described previously by Gordon & Martin (1983) . Dispersed cells from four 25cm2 flasks were added to 2.5 ml of Superbead TM microcarrier inert beads (Flow Laboratories) suspended in an intermittently stirring culture flask (Techne) containing 20 ml of the culture medium described above. The beads were stirred (3 min on, 30 min off) overnight. The number of cells per bead was counted after ethanol fixation and staining with 0.1% methyl violet. A column for perfusion was prepared from the barrel of a 2 ml syringe, plugged with siliconised glass wool. The suspension of beads was poured into the barrel, and the final packed volume was between 1.8 and 2 ml. A second siliconised glass wool plug was placed on the top of the column, and the syringe plunger, with a fine polythene delivery tube inserted through the centre, was then sited on top of the column. The column was perfused from the bottom upwards, at a rate of 0.35-0.375mlmin-', with DMEM and I mg ml-' essentially fatty acid-free bovine serum albumin, equilibrated with 95% air and 5% CO2. Using dextran blue as a marker, it was demonstrated that at this perfusion rate the volume of the system was such that it took 4 min to perfuse it end to end. All studies were undertaken in a room maintained at 33-35°C. The column was perfused for 40 min to allow the system to return to a stable state.
During an experiment, fractions of the perfusate were collected for periods of 1 min, and these were saved for assay of 6-oxo-PGF,,. Cells were stimulated with In further experiments it was shown that repeated 4 min pulses of hCGRP, with 15 min of control perfusate between each, produced stimulations of 6-oxo-PGF,. production which were a little greater with each sequential stimulus (Figure 2) .
The effect of a short 4 min stimulation was compared with that of a subsequent longer 25 min perfusion with hCGRP 10-6 M (Figure 3a) . The level of 6- oxo-PGF,. was greater after the long perfusion compared with the short perfusion, but the levels decreased again despite continued exposure to the hCGRP in the perfusate. The increase in 6-oxo-PGF,, in the superfusate during the longer perfusion with hCGRP 10-6 M contrasted with the reduced levels of 6-oxo-PGF,, seen when a long perfusion of bradykinin followed a short perfusion at the same concentration (Figure 3b ). Similar patterns of 6-oxo-PGF,, levels were seen in different experiments using bradykinin at concentrations varying from 10-0 to 10-6 M. Only a single narrow peak was seen with each bradykinin stimulus, suggesting rapid tachyphylaxis to its effects. Limited availability of the substrate or oxidation of the enzyme by cyclic endoperoxides were unlikely to account for the reduced peak size during the long perfusion with bradykinin 4 x IO-9 M, since a subsequent exposure to a higher concentration of Bk (10-6 M) produced a rapid and greater increase in the superfusate concentration of 6-oxo-PGF1,.
The activation of adenylate cyclase by hCGRP in membranes prepared from cultured human endothelial cells from 21 cords is shown in Figure 4a 
Discussion
Activation of adenylate cyclase by CGRP has been demonstrated in homogenates of spleen and myocardium (Sirgrist et al., 1986) . In these experiments homogenates were prepared from the heterogeneous cells of these tissues, which does not allow precise anatomical localization of the receptors. This point has been partly resolved now by the demonstration of CGRP responsiveness in cultured human endothelial cells.
The interaction of hCGRP with endothelium produces at least two distinct biological responses. (Figure 1 b) may account for the small increases in the response to pulses of hCGRP. If some of the peptide remained bound to its receptors during the wash out, the subsequent pulses would effectively form a cumulative dose-response curve. Results of the prolonged effects of CGRP on forearm blood flow (McEwan et al., 1986) would support this interpretation. Alternatively, the initial concentration of hCGRP might be lowered by binding of the peptide to the tubing and the glass beads despite the presence of albumin in the perfusate.
The concentrations of hCGRP used in our studies were much greater than those required to produce vasodilatation in vitro or in vivo (Brain et al., 1985 (1985) showed that indomethacin had no effect on CGRP-induced vasodilatation in rabbit skin in vivo, and it was proposed that vasodilatation due to CGRP was independent of prostaglandin release. In contrast, the initial flare produced by intradermal injection of CGRP in man is inhibited by aspirin (Barnes et al., 1987) and it has also been shown that vasorelaxation by CGRP of rat aortic strips, preconstricted by noradrenaline, is partially inhibited by indomethacin (Brain et al., 1985) . This may reflect the fact that endothelium is not uniform. Indeed, endothelial cells from microvessels have a quite different profile of prostaglandin production from those derived from large vessels (Gerritsen & Cheli, 1983; Charo et al., 1984) . The studies on the vasodilatation in rabbit skin examined the effect of CGRP on arterioles while the rat aortic strip is a preparation made from a large conductance vessel and its endothelium. The present study has used endothelial cells from a large human vein. Clearly, qualitative variations in endothelium from different species and from different vessels may exist and account for conflicting results.
hCGRP is a potent vasodilator in vivo or in vitro, and the relaxation of vascular smooth muscle is dependent on the presence of an intact vascular endothelium. Endothelial cells are available for activation by hormones in the blood, and are adjacent to vascular smooth muscle cells. The vasodilator properties of hCGRP may therefore be mediated, at least in part, by vasodilator factors including prostacylcin, which are released from vascular endothelium. 
